Document is current
Any future updates will be listed below
-
Authors
Guruprasad, Puneeth
Carturan, Alberto
Zhang, Yunlin
Cho, Jong Hyun
Kumashie, Kingsley Gideon http://orcid.org/0000-0001-7713-1779
Patel, Ruchi P. http://orcid.org/0000-0001-8366-1928
Kim, Ki-Hyun
Lee, Jong-Seo
Lee, Yoon
Kim, Jong Hoon
Chung, Junho
Joshi, Akshita
Cohen, Ivan
Shestov, Maksim
Ghilardi, Guido
Harris, Jaryse
Pajarillo, Raymone
Angelos, Mathew
Lee, Yong Gu
Liu, Shan
Rodriguez, Jesse
Wang, Michael
Ballard, Hatcher J.
Gupta, Aasha
Ugwuanyi, Ositadimma H.
Hong, Seok Jae Albert
Bochi-Layec, Audrey C.
Sauter, Christopher T.
Chen, Linhui
Paruzzo, Luca http://orcid.org/0000-0002-6505-0194
Kammerman, Shane
Shestova, Olga
Liu, Dongfang http://orcid.org/0000-0002-7295-8088
Vella, Laura A.
Schuster, Stephen J.
Svoboda, Jakub
Porazzi, Patrizia
Ruella, Marco http://orcid.org/0000-0003-4301-5811
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R00-CA212302)
Foundation for the National Institutes of Health (AI130197, CA267368)
- License Information
-
More Information
Article History
Received: 8 May 2023
Accepted: 17 April 2024
First Online: 3 June 2024
Competing interests
: M.R. holds patents related to CD19 CAR T cells. AbClon and Penn have filed a provisional patent application for the CART30 used in this project (patent pending). The University of Pennsylvania has filed a provisional patent application on the BTLA knockout to enhance CART immunotherapies (patent pending). M.R. has served as a consultant for nanoString, BMS, GSK, Bayer, GLG, Sana and AbClon. M.R. receives research funding from AbClon, ONI, Lumicks, nanoString and Beckman Coulter. M.R. is the scientific founder and chair of the scientific advisory board of viTToria biotherapeutics. All other authors declare no competing interests.
